sulfamethoxazole brands

29 registered brands containing sulfamethoxazole in Rwanda.

sulfamethoxazole

PubChem CID 5329

Molecular formula: C10H11N3O3S

Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolic acid synthesis due to its structural similarity to an endogenous substrate, para-aminobenzoic acid (PABA). Most bacteria meet their need for folic acid by synthesizing it from PABA, as opposed to Animalia that require exogenous folic acid sources. Sulfamethoxazole competitively inhibits dihydropteroate synthase, the enzyme responsible for bacterial conversion of PABA to dihydrofolic acid. Inhibition of this pathway prevents the synthesis of tetrahydrofolate and, ultimately, the synthesis of bacterial purines and DNA, resulting in a bacteriostatic effect. Sulfonamides are usually bacteriostatic in action. Sulfonamides interfere with the utilization of p-aminobenzoic acid (PABA) in the biosynthesis of tetrahydrofolic acid (the reduced form of folic acid) cofactors in susceptible bacteria. Sulfonamides are structural analogs of PABA and appear to interfere with PABA utilization by competitively inhibiting the enzyme dihydropteroate synthase, which catalyzes the formation of dihydropteroic acid (a precursor of tetrahydrofolic acid) from PABA and pteridine; however, other mechanism(s) affecting the biosynthetic pathway also may be involved. Compounds such as pyrimethamine and trimethoprim, which block later stages in the synthesis of folic acid, act synergistically with sulfonamides. Only microorganisms that synthesize their own folic acid are inhibited by sulfonamides; animal cells and bacteria which are capable of utilizing folic acid precursors or preformed folic acid are not affected by these drugs. The antibacterial activity of the sulfonamides is reportedly decreased in the presence of blood or purulent body exudates. /Sulfonamides/ /Sulfonamides inhibit bacterial growth by preventing para-aminobenzoic acid (PABA) from being incorporated/ into dihydropteroic acid, the immediate precursor of folic acid. Sensitive microorganisms are those that must synthesize their own folic acid; bacteria that can utilize preformed folate are not affected. Bacteriostasis induced by sulfonamides is counteracted by PABA competitively. Sulfonamides do not affect mammalian cells by this mechanism, since they require preformed folic acid and cannot synthesize it. /Sulfonamides/ Sulfonamides are broad-spectrum, bacteriostatic anti-infectives. They are structural analogs of para-aminobenzoic acid and competively inhibit a bacterial enzyme, dihydropteroate synthetase, that is responsible for incorporation of para-aminobenzoic acid into dihydrofolic acid. This blocks the synthesis of dihydrofolic acid and decreases the amount of metabolically active tetrahydrofolic acid, a cofactor for the synthesis of purines, thymidine, and DNA. /Sulfonamides/ The hydroxylamine and nitroso metabolites formed by N4-oxidation of sulfonamides are thought to be involved in the pathogenesis of idiosyncratic reactions to this class of drugs. Idiosyncratic reactions to sulfonamides are characterized by multisystemic toxicity, including hepatitis, nephritis, dermatitis, and blood dyscrasias (aplastic anemia, agranulocytosis). Previously it has been shown that cytochrome p-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite. In this paper the N4-oxidation of sulfamethoxazole by activated monocytes and neutrophils (human and canine) to form sulfamethoxazole hydroxylamine and nitrosulfamethoxazole is reported. The presumed nitroso intermediate was not detected. Purified myeloperoxidase and prostaglandin H synthase were also capable of mediating the oxidation of sulfamethoxazole. The present studies suggest that myeloperoxidase is responsible for the observed oxidation by phagocytic cells. Oxidation by neutrophils may play a role in agranulocytosis, and oxidation by monocytes may facilitate antigen presentation. Extrahepatic bioactivation of sulfonamides by peroxidases in phagocytic cells and other tissues may be important in determining the range of adverse reactions to sulfonamides

Source: PubChem (NCBI) ยท compound 5329

Product Manufacturer Status Country
BALTRIM
Uncoated Tablets
Bal Pharma Registered Rwanda
BALTRIM FORTE
Uncoated Tablets
Bal Pharma Registered Rwanda
BETRIM FORTE
Tablets
Milan Laboratories Registered Rwanda
BETRIM-480 (CO-TRIMOXAZOLE TABLETS BP 480MG)
Tablets
Milan Laboratories Registered Rwanda
BIOTRIM 480MG TABLETS
TABLETS
Biodeal Laboratories Registered Rwanda
BIOTRIM DS TABLETS
Tablets
Biodeal Laboratories Registered Rwanda
BIOTRIM SUSPENSION
suspension
Biodeal Laboratories Registered Rwanda
BRONQUIDIAZINA CR ORAL SUSPENSION
Oral suspension
Faes Farma Registered Rwanda
CO-TRIMOXAZOLE
TABLETS
Aura Lifecare Registered Rwanda
CO-TRIMOXAZOLE 960
Tablets
Aura Lifecare Registered Rwanda
CO-TRIMOXAZOLE-480
Tablets
Aura Lifecare Registered Rwanda
COSATRIM 400/80 TABLETS
Tablets
Cosmos Registered Rwanda
COTRIKANT-480
Tablets
S Kant Healthcare Registered Rwanda
COTRIZIM-480
Uncoated Tablets
Zim Laboratories Registered Rwanda
EMBRACOTRIM 960
Uncoated Tablets
Merit Organics Registered Rwanda
LECOTRIM SUSPENSION
Suspension
Laboratory & Allied Registered Rwanda
LECOTRIM TABLETS
Tablets
Laboratory And Allied Registered Rwanda
ML-COTRI SUSPENSION
Suspension
Milan Laboratories Registered Rwanda
PAEDIATRIC COTRIMOXAZOLE
TABLETS
Lincoln Pharmaceuticals Registered Rwanda
Q-TIB
Tablets
Cipla Registered Rwanda
RENETRIM DS TABLETS
Tablets
Rene Industries Registered Rwanda
RENETRIM TABLETS
Tablets
Rene Industries Registered Rwanda
SULPHATRIM
Oral suspension
Lincoln Pharmaceuticals Registered Rwanda
SULPHATRIM 480
Tablets
Lincoln Pharmaceuticals Registered Rwanda
SULPHATRIM-960 MG
Tablets
Lincoln Pharmaceuticals Registered Rwanda
TRIMAGO ORAL SUSPENSION
Oral liquid Suspension
Agog Pharma Registered Rwanda
TRIMOXOL SUSPENSION
Oral suspension
Dawa Registered Rwanda
UNITRIM DS TABLETS
Tablets
Regal Pharmaceuticals Registered Rwanda
UNITRIM TABLETS
Tablets
Regal Pharmaceuticals Registered Rwanda